For the three months ended March 31, 2026, there were two customers who each individually accounted for greater than 10% of the Company’s total revenues. These two customers accounted for revenues of…
cell lymphoma and a payment of $ million upon receipt of the first regulatory approval for the commercial sale of COPIKTRA in the European Union for the treatment of peripheral T-cell lymphoma, (ii) …
Reciprocal relationship from SNYNF graph: Reciprocal relationship from VSTM graph: cell lymphoma and a payment of $ million upon receipt of the first regulatory approval for the commercial sale of CO…
Verastem, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
VSTM-DEBT-13454
Warrants outstanding: 33792000
90%
xbrl warrant detail from xbrl 2025-12-31.
VSTM-DEBT
Debt stack $85.5M
90%
Market cache reports total debt of $85.5M.
VSTM-DEBT-13455
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
Verastem, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Verastem, Inc..
Verastem, Inc. Ownership
Holder
Name
Confidence
Evidence
VSTM-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 157 tracked holders.